C14orf162 Inhibitors
C14orf162 Inhibitors are a class of chemical compounds that can reduce the functional activity of the protein C14orf162, a protein with unknown function but is involved in MAPK and PI3K/AKT/mTOR pathways. The first six inhibitors, U0126, LY294002, Rapamycin, PD98059, Wortmannin, and SP600125, target the proteins MEK1/2, PI3K, mTOR, MEK, PI3K, and JNK respectively, which are upstream components of these pathways. By inhibiting these upstream components, these inhibitors can indirectly suppress the function of C14orf162 as it is downstream of these proteins in the pathways.
The remaining six inhibitors, SB203580, Akti-1/2, PF-04691502, AZD8055, FR180204, and GSK690693, target p38 MAPK, AKT1/2, PI3K and mTOR, mTOR, ERK, and AKT respectively, which are also essential proteins in the MAPK and PI3K/AKT/mTOR pathways. They affect the pathways by inhibiting the respective proteins, leading to the downstream suppression of C14orf162. SB203580, for instance, specifically inhibits p38 MAPK, a key part of the MAPK pathway, thereby indirectly inhibiting the functional activity of C14orf162. Likewise, Akti-1/2 selectively inhibits AKT1 and AKT2, essential for the PI3K/AKT/mTOR pathway. By suppressing these kinases, it indirectly inhibits C14orf162. Similarly, PF-04691502, AZD8055, FR180204, and GSK690693 inhibit PI3K and mTOR, mTOR, ERK, and AKT respectively, leading to indirect suppression of C14orf162.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K), a key player in the PI3K/AKT/mTOR pathway. By inhibiting PI3K, LY294002 suppresses the downstream AKT activation, which indirectly leads to the inhibition of C14orf162. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of mTOR, a downstream component of the PI3K/AKT/mTOR pathway. Its inhibition leads to the suppression of AKT signaling and indirectly inhibits the function of C14orf162. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor blocking ERK activation in the MAPK pathway. As ERK promotes downstream signaling events where C14orf162 is involved, its inhibition indirectly suppresses C14orf162. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. It blocks PI3K activity, leading to the suppression of AKT signaling and indirectly leading to the inhibition of C14orf162. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective JNK inhibitor, which inhibits JNK activation in the MAPK pathway. As JNK promotes downstream signaling events where C14orf162 is involved, its inhibition indirectly suppresses C14orf162. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The inhibition of p38 MAPK can lead to the indirect inhibition of functional activity of C14orf162. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $208.00 $270.00 | 29 | |
Akti-1/2 selectively inhibits AKT1 and AKT2 in the PI3K/AKT/mTOR pathway. By inhibiting these kinases, Akti-1/2 suppresses the downstream signaling and indirectly inhibits C14orf162. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a potent mTOR inhibitor in the PI3K/AKT/mTOR pathway. By inhibiting mTOR, it suppresses AKT signaling and indirectly inhibits C14orf162. | ||||||
ERK Inhibitor II, FR180204 | 865362-74-9 | sc-203945 sc-203945A sc-203945B sc-203945C | 1 mg 5 mg 10 mg 50 mg | $110.00 $165.00 $239.00 $942.00 | 45 | |
FR180204 is a selective inhibitor of ERK in the MAPK pathway. Its inhibition of ERK leads to the indirect suppression of C14orf162. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is an AKT inhibitor in the PI3K/AKT/mTOR pathway. It suppresses AKT signaling and indirectly inhibits C14orf162. | ||||||